Lecture: Targeting CV risk: Implications for clinical management of patients with T2DM & CVD

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Two choices of drugs that reduce CV risk in T2DM
Two choices of drugs that reduce CV risk in T2DM
CDMC 2018: Shifting gears in the management of diabetes and CVD
Two choices of drugs that reduce CV risk in T2DM
- Prof. John Deanfield, MD
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
CDMC 2018: Shifting gears in the management of diabetes and CVD
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
- Dr. Adie Viljoen, MD
Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
CDMC 2018: Shifting gears in the management of diabetes and CVD
Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
- Prof. Eduard Montanya, MD
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
- Prof. Lars Rydén